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Inappropriate use of antibiotics is rampant in South East Asia1-6 and is a major contributor to 
antimicrobial resistance.7-9 However, data on antibiotic use are scant, few effective 
interventions to improve appropriate antibiotic use have been implemented,10 11 and 
implementation of policies for appropriate use of antibiotics is also poor.12 13 An analysis of 
secondary data on antibiotic use from 56 low and middle income countries found that 
countries reporting implementation of more policies also had more appropriate antibiotic 
use.14 15 Effective policies included having a government health department to promote 
rational use of medicines, a national strategy to contain antimicrobial resistance, a national 
drug information centre, drug and therapeutic committees in more than half of all general 
hospitals and provinces, and undergraduate education on standard treatment guidelines.15 
An updated essential medicines list and national formularies were also associated with lower 
antibiotic use. 
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Antibiotic use in South East Asia and policies to 
promote appropriate use: reports from country 
situational analyses
Kathleen Holloway and colleagues discuss findings from a rapid assessment of antibiotic 
use and policies undertaken by South East Asian countries to drive further actions to reduce 
inappropriate use
Key messages
•   Country situational analyses pro-
vide rapid assessment of antibiotic 
use and policies, particularly where 
infrastructure for routine monitoring 
is lacking, so help to build political 
will and government capacity to take 
action to improve the appropriate use 
of antibiotics 
•   South East Asian countries have high 
antibiotic use, and poor implementa-
tion of policies to encourage appropri-
ate use
•   Measures such as a dedicated gov-
ernment unit for antimicrobial 
stewardship, a national strategy to 
contain antimicrobial resistance, 
updated standard treatment guide-
lines, hospital drug and therapeutic 
committees, public education, and 
restriction of newer antibiotics being 
available  without prescription must 
be implemented
I
nappropriate use of  antibiotics  is 
rampant  in South East Asia1-6 and 
is a major contributor to antimicro-
bial resistance.7-9 However, data on 
antibiotic use are scant, few effec-
tive interventions to improve appropriate 
antibiotic use have been implemented,10 11 
and implementation of policies for appro-
priate use of antibiotics is also poor.12 13 
An analysis of secondary data on antibi-
otic use from 56 low and middle income 
countries found that countries reporting 
implementation of more policies also 
had more appropriate antibiotic use.14 15 
Effective policies included having a gov-
ernment health department to promote 
rational use of medicines, a national strat-
egy to contain antimicrobial resistance, a 
national drug information centre, drug 
and therapeutic committees in more than 
half of all general hospitals and provinces, 
and undergraduate education on stand-
ard treatment guidelines.15 An updated 
essential medicines list and national for-
mularies were also associated with lower 
antibiotic use.
Many   h igh   l eve l   f o rums   have 
recommended that countries undertake 
routine monitoring of antibiotic use and 
use an integrated health systems approach 
to improve access to and use of medicines, 
including antibiotics.16-18 Most South East 
Asian countries lack the infrastructure for 
this, and the responsibility for medicines 
management  is often divided between 
different government units with no clear 
accountability. Since 2010, South East 
Asian countries have been conducting 
national situational analyses on medicines 
management every four years,19 supported 
by  the World  Health  Organization.20 
This process involves rapid systematic 
data collection on use and availability 
of medicines, including antibiotics, and 
implementation  of  policies  to  ensure 
appropriate  use.  A multidisciplinary 
government team of four to eight people 
conducts this analysis over two weeks using 
a predesigned workbook tool. The process 
ends with a national workshop to identify 
priorities for action.19
We present key findings from published 
reports of the situational analyses done 
during 2010-15 19 and propose next steps 
to improve antibiotic management.
Methods
We reviewed all the country reports of the 
situational analyses published on the web-
site of the WHO Regional Office for South-
East Asia (WHO/SEARO)19 and extracted 
data on antibiotic use  in primary care 
facilities in the public sector, opinions of 
health workers on antibiotic use, and poli-
cies to encourage appropriate use. Box 1 
summarises the methods for the country 
situational analyses. 19
All results presented here were taken 
from the country reports.19 For indicators 
of antibiotic use, the averages across all 
facility types are presented. Where possible 
(in  the  later  second  round  situation 
analyses), we calculated the median, and 
the 25th and 75th centiles for each country. 
No further statistical analysis could be done 
because of the small sample sizes and 
convenience sampling.
For antibiotic management, we focus on 
policies known to be associated with more 
appropriate use.15 We present data from 
all countries to give a regional picture, but 
we have not made comparisons between 
countries or over  time as  the data are 
insufficient for this purpose.
Findings
National situational analyses were con-
ducted in all 11 countries of the South-East 
Asia region during 2010-13 and repeated in 
eight countries during 2014-15. In India, 
the analysis was done in only two states. In 
the first round, the data collection tool was 
being developed by WHO, government staff 
were less involved, and it was not possible 
to visit the designated number of health 
facilities, or collect data on antibiotic use 
in upper respiratory tract infection in all 
facilities. In the second round, data collec-
tion was done by a full government team 
using the predesigned workbook tool,19 
and it was possible to visit more facilities. 
The tool was useful for standardised data 
collection, and it may be further modified 
based on the experience in countries.
Overall, medicines management  is 
under-resourced  in  terms  of  funding 
and human resources in most countries. 
Partner support from donors, bilateral 
and multilateral  agencies,  and  non-
governmental agencies is generally limited 
and fragmented. In most countries, drug 
management, centrally and at facilities, is 
done manually leading to poor forecasting, 
quantification and stock management. 
Only three of 11 countries reported any 
monitoring of antibiotic use, either by 
collecting prescribing data or monitoring 
antibiotic use in hospitals. Drug regulatory 
authorities  are  under-resourced  and 
implementation of drug policies about 
supply, selection, use, and regulation is 
suboptimal.19
Table 1 summarises antibiotic use in 
primary care facilities in the public sector, 
and the presence of policies to promote 
more appropriate use based on selected 
indicators from the most recent situational 
analyses.19 Antibiotic use was high  in 
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all  countries. Much of  it was possibly 
inappropriate since most cases of upper 
respiratory tract infection in primary care 
are viral and do not need an antibiotic.24 
Fig 1 and 2 show the median and centile 
range of antibiotic use across facilities by 
country, and also indicate high antibiotic 
usage. Direct comparison between countries 
was not possible because the data from the 
individual surveys were not generalisable, 
the case mix varied, the capacity of health 
workers to make accurate diagnoses and 
their diagnostic terminology varied, and the 
drugs available were different. However, the 
lowest antibiotic use for upper respiratory 
tract infection was in Bhutan and Thailand, 
both of which had excellent availability of 
drugs at the facilities.19
Implementation  of  recommended 
policies to reduce inappropriate use of 
antibiotics14 15 was poor.19 Antibiotics 
were available over the counter without 
prescription in all countries, even though 
this  is  illegal  in  all  countries  except 
Thailand and East Timor.
Qualitative  information on possible 
causes of  inappropriate antibiotic use 
was collected by interviewing healthcare 
workers in all countries. Between three 
and  10  health  workers  from  each  of 
200 facilities (depending on size) were 
interviewed. Many health workers were 
aware that antibiotics were misused and 
cited various reasons, including patient 
demand, poor drug supply, and lack of 
diagnostic facilities, training, appropriate 
information, and time. Box 2 gives some 
examples of the views of the health workers 
taken from the country reports.19.
Antibiotic use was heavily influenced by 
availability of drugs, staffing policies, and 
implementation of regulations, as well as 
the knowledge, beliefs, and qualifications 
of the health workers. Private pharmacy 
owners and dispensers in many countries 
stated that if they did not sell antibiotics 
without prescription,  they would  lose 
business  because  the  patients would 
simply go elsewhere. These views may not 
be representative of practice in the entire 
country or region, but previous studies 
have reported all these causes.23
The  process  ended  with  national 
workshops to develop recommendations 
based on the findings with participation 
from  government  officials,   health 
workers,  and  partner  organisations. 
Recommendations  were  made  in  all 
countries19 to establish and strengthen 
hospital drug and therapeutic committees; 
undertake public education on antibiotic 
use; enforce prescription only availability 
for newer antibiotics; and establish a 
government unit with direct responsibility 
for monitoring  use  of medicines  and 
coordinating implementation of policies 
to encourage rational use.
In eight countries where two situational 
analyses were done, the action taken on 
the recommendations made in the first 
situational analysis was assessed. Table 2 
summarises antibiotic use in public sector 
primary care in these eight countries in 
the first and second analyses, and the 
measures  that were  taken  to  improve 
appropriate use.
Antibiotic use in primary care remained 
high in all countries, apart from in Thailand 
where  it  appeared  to  have  decreased 
substantially. Thailand was also the only 
country  to  report  specific nationwide 
Box 1: Summary of methods for AMR situational analysis
The workbook tool used for the situational analysis built on other tools 21 and was developed by WHO/SEARO in the first round of situational 
analyses in all 11 countries during 2010-13. The tool was piloted for use by government staff in the second round of analyses in eight countries 
during 2014-15.  
The situational analysis approach was developed in the WHO South-East Asian region at the request of member states 20 22 but is suitable for 
use in other low and middle income countries.
Methods
Over two weeks the analysis team visited all major ministry of health departments and agencies responsible for drug supply, selection, 
use, regulation, drug policy, insurance, and health professional training to understand what each unit did, and what policies were in 
place. The team also visited healthcare facilities, with the aim of visiting at least 20 facilities, two of each type of public health facility 
(primary care centres, secondary, and tertiary hospitals) plus private pharmacies in at least two provinces/regions, as selected by 
the ministry of health.
Data collection and analysis
Data were collected using a predesigned workbook tool 19 (see supplementary data on bmj.com) by a team of four to eight staff nomi-
nated by the government, with at least one team member from each of the government departments responsible for drug supply, 
selection, use, regulation, and policy. Staff at the central level were interviewed using the open questions in the workbook tool about 
the health system and policies in place.
At each health facility, the team reviewed 30 primary care outpatient encounters (using documentation available at the facility, such as 
prescriptions held in the pharmacy or by the patient, paper slips in the pharmacy, patient records, or outpatient registers). The means 
for standard indicators of medicines use 21 (including the percentage of patients receiving an antibiotic) were calculated for each facility 
and each category of facility. 
Additionally, antibiotic use in 30 cases of upper respiratory tract infection was reviewed, although a lack of records on diagnosis 
made this difficult in some countries. The percentage of cases with upper respiratory tract infection receiving an antibiotic was 
calculated for each facility and used to calculate the average for each type of facility. The basis for a diagnosis of upper respiratory 
tract infection was recorded—for example, runny nose, rhinitis, cough, cold, sore throat, viral acute respiratory infection, acute 
laryngitis, acute bronchitis, earache, and otitis media.
The availability and procurement prices of essential medicines was also checked. 
The team interviewed health workers (including the health facility manager, a prescriber in the outpatient department, the head of 
the pharmacy, a dispenser, a nurse, and sometimes other staff) using the open questions in the workbook about management of 
medicines and implementation of policies, and any problems. 
Cross-cutting descriptive analysis was done each day and presented by the team at a national workshop at the end of the two weeks. 
The teams wrote country reports in the workbook tool format, which were published on the WHO/SEARO website after government 
approval.
WHO facilitated and supervised the entire process, including preparation, data collection and analysis, conducting the national 
workshop, and writing and publishing the country reports.
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actions to reduce inappropriate antibiotic 
use.24 These included monitoring use, a 
project to improve prescribing behaviour25 
using multifaceted behaviour  change 
interventions, strengthening hospital drug 
and therapeutic committees, and regularly 
updating  its  essential medicines  list. 
However, the figures should be interpreted 
with caution. Direct comparison between 
the two periods is not possible because of 
the small sample sizes and the selection 
of  different  facilities.  Furthermore, 
some  countries  reported  changes  in 
the availability and  types of essential 
medicines which  could have  affected 
measurement of antibiotic use between 
the two periods.
Benefits and limitations of country situational 
analyses
The situational analyses enabled the rapid 
collection of data sufficient to show wor-
ryingly high use of antibiotics in primary 
care, and poor implementation of poli-
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Fig 2 | Median (25th to 75th centiles) 
percentage of patients with upper respiratory 
tract infection prescribed antibiotics across 
all surveyed public primary care facilities in 
eight South East Asian countries
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Fig 1 | Median (25th to 75th centiles) 
percentage of outpatients prescribed 
antibiotics across all surveyed public primary 
care facilities in eight South East Asian 
countries (n=number of facilities surveyed)
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cies to promote more appropriate use.15 
Although the data are limited, and not 
generalisable to the national situation, 
they have identified serious problems, and 
provided evidence to advocate for feasible 
solutions. The data highlight to govern-
ments ongoing antibiotic misuse in public 
primary care, possible reasons for misuse, 
and the urgent need to implement policies 
to encourage more appropriate use.19 The 
analyses have also allowed some monitor-
ing of progress. Since the assessment is 
completed within two weeks, it is cheap 
and flexible. Involvement of government 
staff in data collection helps build their 
capacity to assess antibiotic use and policy 
implementation, and increases the likeli-
hood of government follow up. It remains to 
be seen if greater government involvement 
guarantees action.
Data  collection  in  the  private  and 
hospital sectors was too limited for useful 
regional analysis. A substantial proportion 
of antibiotic use occurs in primary care, 
however, and we expect private sector 
antibiotic prescribing  to be similar  to 
that in the public sector.23 The quality of 
the data may have been affected by time 
and resource constraints. However, error 
was minimised by WHO staff supervising 
all data collection. Furthermore, similar 
results  about  antibiotic management 
in South East Asia have been reported 
elsewhere.1-7 10-13
Developing political will and an enabling 
environment
The situational analyses would not have 
been possible without political will. Devel-
oping a mandate for action took six years, 
and involved two regional meetings with 
experts and senior government officials to 
finalise the process.26 27 The recommenda-
tions of each meeting were incorporated 
into two WHO regional resolutions adopted 
by the governments of member states of the 
South-East Asia region.20 22
Even with a mandate, many government 
officials feared that they might be blamed 
for any negative findings, and this may 
have led to a reluctance to collect and share 
data on antibiotic management. However, 
constant reassurance by WHO that the 
purpose of the situation analyses was not to 
find fault but to identify weaknesses in the 
healthcare system, and possible solutions, 
reduced staff fears, and resulted in free 
and  frank discussions  in  the national 
workshops.19
In  conclusion,  inappropriate use of 
antibiotics is high, and implementation of 
policies to encourage more appropriate use 
is poor in many South-East Asian countries.
We recommend that countries take the 
following actions:
•   Undertake regular situational analyses 
to monitor antibiotic use, and policy 
implementation as already mandated 
by WHO member states20
•   Develop  a  national  coordinating 
mechanism, and establish a government 
unit  to  regularly monitor  the use of 
medicines and antibiotics, and policy 
implementation
•   S t rengthen   hospi ta l   drug   and 
therapeutics committees, and update and 
Box 2: Health worker comments relating to inappropriate antibiotic use 19
• “How can I make a proper diagnosis in one minute?” (Doctor in Bangladesh)
•  “According to STGs [standard treatment guidelines] for fever, coughs and colds, we should 
give paracetamol for a few days and only give antibiotics if there is no response, but I like to 
give the complete treatment (ie, antibiotics) from the start.” (Doctor in Sri Lanka)
•  “For children under 5 years with pneumonia I must give amoxicillin according to the IMCI 
[Integrated Management of Childhood Illness] guidelines. Since we are short of amoxicillin 
and have short-dated chloramphenicol syrup, I am prescribing chloramphenicol syrup to 
children of more than 5 years with pneumonia in order to use up the stock.” (Health post 
in-charge (senior auxiliary health worker who is a paramedical staff of two to three years 
training) in Nepal)
•  “We have a lot of soon-to-expire erythromycin so we are pushing it to the dispensary and we 
will finish it in a few days.” (Pharmacy technician in East Timor)
•  “I do not like to go to the hospital because of the long wait and the difficulty to see the correct 
doctor.” (Pharmacy customer in Bhutan)
•  “We urgently need national standard treatment guidelines to ensure that drugs are used 
properly and not wasted.” (Senior policy maker in Myanmar)
•  “We have to give antibiotics like azithromycin and cefixime because the patients have 
already been prescribed the simpler antibiotics by unqualified practitioners.” (Medical 
officer in Rajasthan, India)
Table 2 | Antibiotic use in public sector primary care facilities and policy changes in eight countries for which a situational analysis was done 
twice during 2010-1519
Country
No of public facilities, patient 
encounters (No with URTI data)
Average % (range) of 
outpatients given antibiotics 
across facility type
Average % (range) of patients 
with URTI given antibiotics 
across facility type New policies implemented between 2010-12 
and 2014-152010-12 2014-15 2010-12† 2014-15† 2010-12† 2014-15†
Bangladesh 4, 120 (0) 10, 300 (6, 183) 48 (34-74) 31 (19-54) — 59 (59-60) None. Variable drug availability in terms of supply 
and type
Bhutan 8, 240 (0) 13, 390 (12, 360) 33 (31-34) 41 (33-49) — 34 (26-42) Some monitoring and continuing medical education, 
updated essential medicines list and standard 
treatment guidelines, and good drug availability
Maldives 5, 150 (0) 8, 240 (8, 215) 38 (35-43) 24 (15-34) — 43 (34-48) None. Decreased drug availability
Myanmar 10, 300 (8, 90) 14, 420 (11, 360) 38 (27-56) 47 (34-54) 83 (72-100) 87 (73-96) None. Increased drug availability
Nepal 13, 390 (9, 110) 10, 300 (7, 350) 47 (21-54) 44* (39-46) 73 (72-74) 66 (63-71) Non-governmental organisation rational use of 
medicine project in a few districts. Variable drug 
availability
Sri Lanka 6, 180 (0) 10,300 (8, 271) 49 (22-66) 56 (45-67) — 70 (47-85) Drug and therapeutic committees started in 2015. 
Variable drug availability
Thailand 9, 270 (6, 73) 14, 420 (13, 485) 30 (23-45) 12 (11-14) 57 (54-62) 43 (20-52) Monitoring use, updated essential medicines list, drug 
and therapeutic committees, and antibiotic smart use 
and PLEASE projects†¶
East Timor 10, 300 (8, 153) 16, 480 (15, 334) 50 (42-75) 43 (39-50) 77 (69-88) 55 (47-66) None. Decreased drug availability
URTI=upper respiratory tract infection.
*Includes one medical college in Nepal offering some public services.
†Antibiotic smart use project, started in 2007, consists of multifaceted interventions at the individual, organisational, network, and policy levels aimed at changing behaviour, maintaining the 
changes, and scaling up the project. Activities vary across institutions. ¶PLEASE project, started in 2014 in 71 hospitals. It consists of: pharmacy and therapeutics committee (P), labelling and 
leaflet (L), essential tools for rational use of medicines (E), awareness of rational use among prescribers and patients (A), special population care (S), and ethics in promotion (E).
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implement national standard treatment 
guidelines  by  training health  staff, 
monitoring the use of medicines, and 
ensuring that the drug supply matches 
what is recommended in the guidelines
•   Invest in public education, and regulate 
over-the-counter availability of newer 
antibiotics.
While the member state resolutions have 
enabled the country situational analyses 
on medicines management to be done, 
constant follow up by governments, WHO 
and partners, and appropriate investment 
will be needed to make progress.
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